Unknown

Dataset Information

0

Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy.


ABSTRACT: Adoptive cell therapy with virus-specific T cells has been used successfully to treat life-threatening viral infections, supporting application of this approach to coronavirus disease 2019 (COVID-19). We expand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T cells from the peripheral blood of COVID-19-recovered donors and non-exposed controls using different culture conditions. We observe that the choice of cytokines modulates the expansion, phenotype, and hierarchy of antigenic recognition by SARS-CoV-2 T cells. Culture with interleukin (IL)-2/4/7, but not under other cytokine-driven conditions, results in more than 1,000-fold expansion in SARS-CoV-2 T cells with a retained phenotype, function, and hierarchy of antigenic recognition compared with baseline (pre-expansion) samples. Expanded cytotoxic T lymphocytes (CTLs) are directed against structural SARS-CoV-2 proteins, including the receptor-binding domain of Spike. SARS-CoV-2 T cells cannot be expanded efficiently from the peripheral blood of non-exposed controls. Because corticosteroids are used for management of severe COVID-19, we propose an efficient strategy to inactivate the glucocorticoid receptor gene (NR3C1) in SARS-CoV-2 CTLs using CRISPR-Cas9 gene editing.

SUBMITTER: Basar R 

PROVIDER: S-EPMC8260499 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8652867 | biostudies-literature
| S-EPMC7077957 | biostudies-literature
| S-EPMC7474265 | biostudies-literature
| S-EPMC4485840 | biostudies-other
| S-EPMC7594488 | biostudies-literature
| S-EPMC7653090 | biostudies-literature
| S-SCDT-EMBOJ-2020-106267 | biostudies-other
| S-EPMC7398110 | biostudies-literature
| S-BSST379 | biostudies-other
| S-EPMC7947351 | biostudies-literature